热门资讯> 正文
BridgeBio软骨发育不全资产因figratini获得FDA突破性治疗状态
2024-09-17 23:49
- The U.S. FDA has granted BridgeBio Pharma's (NASDAQ:BBIO) achondroplasia candidate infigratinib FDA Breakthrough Therapy Designation.
- The status provides for faster review of experimental drugs that are seen as having potentially significant improvement over currently approved therapies.
- The classification was granted based on results from a cohort of PROPEL 2 data, which showed infigratinib resulted in a statistically significant annual height velocity increase. The mean change from baseline was +2.51cm/yr at one year, and +2.50 cm/yr at 18 months.
- A statistically significant improvement in body proportionality at 18 months was also seen.
- PROPEL 3, a phase 3 trial, is enrolling, and is expected to finish enrollment by the end of the year.
More on BridgeBio Pharma
- BridgeBio: With HELIOS-B Overhang Removed, Focus To Turn To Approval And Launch Of Acoramidis
- BridgeBio: PDUFA Date Expected In November 2024 Could Shift Momentum
- BridgeBio Pharma's Acoramidis Leads Promising Pipeline With FDA Approval On Horizon
- BridgeBio stock slides on discontinuation of CAH gene therapy
- BridgeBio gets FDA RMAT status for Canavan disease gene therapy
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
